Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a company name.

REQUEST A FREE TRIAL

Lipocine Inc.

Name: Lipocine Inc. - BioCentury Company Profiles - BCIQ
Creator: Biocentury

Headquarters: Salt Lake City, UT, United States of America

Website: http://www.lipocine.com

Year Founded: 1997

Status: Public

Industry Sector: HealthTechnology

CEO: Mahesh V. Patel, PhD

Number Of Employees: 16

Enterprise Value: $4,828,997

PE Ratio: 656.86

Exchange/Ticker 1: NASDAQ:LPCN

Exchange/Ticker 2: N/A

Latest Market Cap: $17,915,600

BioCentury | Nov 10, 2022

Data Byte

Drug development for preterm birth still largely a no-fly zone

Of five disclosed programs to prevent preterm birth, three are preclinical while one clinical program was recently deprioritized

BioCentury | Mar 30, 2022

Product Development

March 29 Quick Takes: Pfizer preps etrasimod submissions after second Phase III readout

Plus Innovent, Lilly expand oncology partnership and updates from InnoRNA, ImmunoGen and more

BioCentury | Sep 1, 2020

Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

Mylan, Biocon launch long-acting insulin biosimilar in U.S. Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:532523) launched Semglee insulin glargine in the U.S. at a wholesale acquisition

BioCentury | May 14, 2019

Company News